Testing laboratories: how they are bought, sold, and valued

What does a testing laboratory licence authorise, and what is it called in each state?

It authorises receiving samples of cannabis and cannabis products from other licensees, analysing them, and issuing the certificate of analysis that a batch needs before retail sale. A lab does not grow, make, or sell cannabis. Its product is a test result.

State	Licence name	Core requirement	Independence rule
California	Type 8 Testing laboratory	Must obtain and maintain ISO/IEC 17025 accreditation; an interim licence is available while working toward it	No other licence type, and no financial interest in any other licence type
Michigan	Marihuana safety compliance facility	Tests for potency and contaminants for other licensees	No shared ownership with a grower, processor, retailer, or microbusiness
Massachusetts	Independent Testing Laboratory	Must be “properly accredited” to test under Commission protocols	A separate Standards Laboratory type verifies other labs’ results

Typical compliance panels cover cannabinoid potency, pesticides, heavy metals, residual solvents, microbial contaminants, mycotoxins, moisture or water activity, and foreign material. The exact analytes and action limits are set state by state, so a method validated in one state is not automatically compliant in another.

How does a testing lab make money?

A lab sells compliance panels to cultivators, manufacturers, and, in California, distributors, plus optional research and development tests such as terpene profiles and in-process potency checks. Revenue is samples times price per sample. Costs are mostly fixed: scientists, instruments and service contracts, consumables and reference standards, accreditation and proficiency testing, a laboratory information management system, and sample couriers.

That cost structure makes utilisation everything.

Illustrative lab economics.

Line	At 800 samples a month	At 1,200 samples a month
Average revenue per sample	$300	$300
Monthly revenue	$240,000	$360,000
Variable cost at $70 per sample	$56,000	$84,000
Fixed cost	$160,000	$160,000
Monthly operating profit	$24,000	$116,000

The prices, volumes, and costs are assumptions for arithmetic, not market quotes. A 50% rise in volume produces almost five times the profit. The reverse is what happens when a lab loses two large clients.

Three forces set volume and price:

1. Batch counts, not dollar sales. Testing demand follows the number of batches produced. Headset reported unit sales up 5.5% against dollar sales up 0.8% for the 12 months to June 2026, so volumes have held up better than client revenues. But clients under margin pressure push hard on lab fees.
2. Batch-size rules. When a state raises the maximum batch size, the same harvest needs fewer tests. This is a regulatory risk unique to labs.
3. Client consolidation and distress. Labs extend credit to growers and processors. In oversupplied states those clients fail, and the lab’s receivables fail with them. See how oversupply and price compression affect value.

The integrity problem

Flower sells partly on its THC percentage, so producers have a motive to use whichever lab reports the highest number. Labs that refuse to play lose clients to labs that do. Regulators have responded on two fronts.

Enforcement against labs. MJBizDaily has reported a fourth California testing lab losing its licence in that state’s crackdown. Enforcement also carries risk for labs that contest it: California suspended a prominent lab in April 2025 over alleged potency inflation and false contaminant results, and although an administrative law judge later found the state’s evidence insufficient, the business remained closed. A suspension can end a lab even if the lab ultimately wins.

Rules against lab shopping. Under Massachusetts Administrative Order No. 4, effective 1 April 2025, a licensee must submit one test sample package to a single Independent Testing Laboratory for the whole compliance panel. Splitting tests among labs is no longer allowed, and a second lab may be used only by approved subcontract where the first lacks the capability or has a conflict.

For a buyer, this cuts both ways. A lab with conservative, defensible results may have lost share in the past and stand to regain it as enforcement tightens. A lab with market-leading potency numbers may be carrying a liability.

How is a testing lab valued?

On normalised earnings, tested hard for client concentration and enforcement risk, with the instruments and accreditation as a floor. The general framework is under valuation methods by licence type. Lab-specific points:

• No public deal data. Private lab sales rarely disclose prices. Treat any quoted “lab multiple” as opinion.
• Recurring volume by client. Monthly sample counts by client for 24 months show stickiness better than revenue does.
• Concentration. A lab where three clients supply half the samples is priced for the loss of one of them, often through an earn-out.
• Scope of accreditation. Every method on the scope is revenue the buyer can earn on day one. Methods still in validation are not.
• Instruments. Chromatography and mass spectrometry systems have resale markets outside cannabis, which supports an asset floor better than grow or extraction equipment does. Financed instruments reduce the price by the debt.
• Licence scarcity. Few states cap lab licences, so the paper rarely carries value by itself. See licence value in capped vs uncapped states.
• Compliance record. Covered under how compliance history affects value; for a lab it is the central issue, not a side issue.

Who buys testing labs?

The independence rules remove nearly every strategic buyer in cannabis. No cultivator, manufacturer, retailer, or multi-state operator can buy a California or Michigan lab while keeping its other licences. The realistic buyers are:

1. Other cannabis labs and multi-state lab groups adding a state or buying out a local competitor’s client book.
2. Analytical laboratories from adjacent fields, such as environmental, food, or agricultural testing, that already run the same instruments and quality systems.
3. Scientist-operators, often the existing laboratory director or management team.
4. Private investors and family offices with no other cannabis holdings. Investors with a diversified cannabis portfolio are usually conflicted out.

Because the pool is small, confidentiality matters more than usual: the likely buyers are the seller’s direct competitors, and clients who hear of a sale may move their samples. See selling a cannabis business confidentially. Bank and SBA loans are unavailable for a licensed marijuana testing lab, so deals rely on cash, seller financing, and instrument finance.

Selling a testing lab: what to prepare

1. Sample volume and revenue by client and by test type, monthly for 24 months, exported from the laboratory information management system.
2. Accreditation file. Current certificate and scope, the last two assessment reports, corrective actions, and proficiency-test results.
3. Regulator correspondence. Every inspection, audit, reference-sample comparison, and notice, with responses.
4. Personnel. Qualifications of the laboratory director, quality manager, and analysts, and agreements that keep them in place.
5. Instrument schedule. Make, model, age, ownership or lease status, service contracts, and validation records.
6. Aged receivables, with a realistic write-down of balances owed by distressed clients.
7. Pricing agreements with major clients, including any change-of-control terms.

Buyer due diligence specific to testing labs

Alongside the general due diligence checklist, test these:

• Data integrity. Have an independent analytical chemist review raw instrument data, audit trails, and calibration records for a sample of reported results. Look for manual integration changes, deleted runs, and results reported without supporting data.
• Potency distribution. Compare the lab’s reported THC results with state or market averages. Results clustered well above the market need an explanation.
• Failure rates. A lab that almost never fails a sample for microbials or pesticides is either serving unusually clean clients or not finding what is there.
• Proficiency tests and regulator round-robins. Any unsatisfactory results and what was done.
• Sample chain of custody in the track-and-trace system, including sample destruction records.
• Client overlap with the buyer. If the buyer already runs a lab in the state, how much volume is truly additive.
• Liability exposure. Professional liability cover, claims history, and any product recalls traced to the lab’s certificates.
• Hemp testing revenue. Separate it. Demand may shift when the federal hemp definition tightens on 12 November 2026 for cannabinoids the plant cannot naturally produce and on 11 December 2026 for the total-THC test and related limits. Background is on the hemp vs marijuana page.

Transfer and approval quirks for testing labs

A lab sale is a regulator-approved change of ownership, with extra layers:

• Every investor is screened for conflicts. California’s bar applies to any person with a financial interest, so one passive investor in the buyer’s fund who also owns a stake in a dispensary can block the deal. Map the buyer’s ownership against the financial interest rules before signing.
• Employees count too. California also prohibits a lab from employing anyone who works for a non-lab licensee.
• Two approvals, not one. The state regulator approves the owners; the accreditation body must be satisfied that the quality system and technical personnel continue.
• Named director. A change of laboratory director generally needs its own notice or approval, and the lab cannot run without one.
• Relocation is slow. Moving instruments means revalidation and an accreditation update as well as a new premises approval, so most buyers keep the site. Check the lease terms under landlord consent and cannabis lease clauses.
• Operations cannot pause. Clients need results in days. The seller runs the lab until approval, and any interim management agreement must leave control, and scientific independence, with the licensee.

280E exposure for testing labs

Unsettled. Section 280E applies to a business that consists of trafficking in Schedule I or II substances. A lab possesses small samples and destroys them; it does not buy or sell cannabis. Advisers differ on whether that is trafficking, and there is no Tax Court decision squarely on cannabis labs. Some labs file as ordinary service businesses and deduct their expenses; others take a conservative position. The practical steps are on the 280E by licence type page: ask for the lab’s written tax position, read how returns were actually filed, and size any tax holdback to the open years.

The exposure has narrowed. Samples from state medical marijuana licensees have involved a Schedule III substance since the 28 April 2026 order, so only the adult-use share of a lab’s work raises the question at all. Labs that also test hemp, food, or environmental samples have a further argument that those are separate lines of business.

This page is educational and is not legal or tax advice. If you are weighing the sale or purchase of a testing lab, a confidential intro call is the place to start.